ARIBIO
Holding Companies & Conglomerates · South Korea · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Seoul-incheon Route Yeongdeungpo-gu, Seo...Phone Number
+82 226370009Website
www.aribio.comRevenue
<$5 MillionIndustry
ZI Rank: 6
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
2
2
4
5
6
About ARIBIO
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer's disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.Explore more
ARIBIO Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ARIBIO your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
ARIBIO, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when ARIBIO launches new products
Check out if ARIBIO is spiking on competitors!
Earning: See what the market has to say on ARIBIO recently announced quarterly report
Click to see if ARIBIO had a recent Job posting/layoffs
Funding: Get notified immidiatlly once ARIBIO has new funding data
Congratulate Masked Content for being promoted to Masked Content at ARIBIO
Check if ARIBIO has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
ARIBIO is experiencing very low activity levels compared to other companies in the Holding Companies & Conglomerates sector.
What does this means?
ARIBIO is drawing exceptional interest within the Holding Companies & Conglomerates industry, suggesting notable developments or strong market momentum, learn more about ARIBIO.
ARIBIO Tech Stack
A closer look at the technologies used by ARIBIO
See more technologies
ARIBIO News & Media
AriBio Completes Treatment Phase of Global Phase 3 POLARIS-AD Trial of AR1001 for Early Alzheimer’s Disease
Pivotal Phase 3 registration trial advances to database lock and analysis; Topline results expected in Q4’26; Results planned for presentation at CTAD 2026 SEONGNAM-SI, SOUTH KOREA, August 3, 2026 /EINPresswire.com/ -- AriBio Co., Ltd., a clinical- …Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease
SHANGHAI and SEONGNAM, South Korea, May 13, 2026 /PRNewswire/ -- On 13 May, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) and AriBio Co., Ltd. ("AriBio"), a biopharmaceutical company focused on neurodegenerative diseases, today jointly...AriBio and RESTARI Announce Exclusive License Agreement for a Novel Program in Polycystic Kidney Disease and Cystic Liver Diseases
AriBio Co., Ltd., a Phase 3 biopharmaceutical company, RESTARI, a company focused on severe kidney diseases, today announced that the companies have entered into an exclusive license and commercialization agreement for the development of a small molecule for certain indications related to...AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer’s Disease
Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) -- AriBio Co., Ltd. ("AriBio"), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively “Arcera”), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer’s disease.
Read more news
Top Holding Companies & Conglomerates Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ARIBIO
Sign Up For FreeTo access detailed company insights
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer's disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the... Read More
